Mutations in BRAF or KRAS, that rarely coexist in CRC, constitutively activate the MAPK signaling pathway, which is involved in the regulation of several cellular processes, and inhibit the apoptosis mechanism, thus supporting tumor cell proliferation. The gene discussed is BRAF; the disease is colorectal carcinoma.